Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10023574 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

Patent 10023574 was granted and assigned to Boehringer Ingelheim on July, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Boehringer Ingelheim

Current Assignee

Boehringer Ingelheim

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

10023574

Date of Patent

July 17, 2018

Patent Application Number

15801442

Date Filed

November 2, 2017

Patent Citations Received

‌

US Patent 11033552 DPP IV inhibitor formulations

‌

US Patent 11911388 Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

‌

US Patent 11291668 Uses of DPP IV inhibitors

‌

US Patent 11919903 Polymorphs

‌

US Patent 11911387 Vasoprotective and cardioprotective antidiabetic therapy

‌

US Patent 10301313 Polymorphs

‌

US Patent 10668074 Uses of DPP IV inhibitors

‌

US Patent 10973827 DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation

Patent Primary Examiner

‌

Deepak R Rao

Patent abstract

The present invention relates to substituted xanthines of general formula

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10023574 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API